{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-066931","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.971033+00:00","generated_at":"2026-06-04T22:05:04.929462+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Catalyst launches AGAMREE (vamorolone) in US for Duchenne Muscular Dystrophy","bullets":["AGAMREE (vamorolone) oral suspension 40 mg/mL now commercially available by prescription for DMD patients aged 2+.","FDA approved Oct 26, 2023; launch follows approval with nationwide specialty pharmacy network.","Pivotal Phase 2b VISION-DMD study showed comparable efficacy with reduced bone health and growth side effects vs. standard corticosteroids.","Catalyst Pathways patient support program provides one-on-one education and financial assistance for eligible patients.","DMD affects ~11,000–13,000 US patients; ~70% currently on corticosteroid therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-066931","json":"https://secwatch.observer/filing/0001193125-24-066931.json","markdown":"https://secwatch.observer/filing/0001193125-24-066931.md","text":"https://secwatch.observer/filing/0001193125-24-066931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524066931/0001193125-24-066931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524066931/d798971d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:05:04.929462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}